To conduct the study, a group of researchers used several in vivo and ex vivo murine models. A rat model was employed to study cardioprotection of CgA in the presence of Doxo, while a mouse model was used to monitor antitumor activities. The study proved that during treatment with Doxo, the release of CgA in the blood was reduced. In addition, when the plasma levels of CgA were restored, the heart was protected from Doxo-dependent cardiotoxicity without impairing the antitumor effect of Doxo.
Together, these findings suggest that monitoring plasma levels of CgA before and after chemotherapy in cancer patients might provide important prognostic information regarding drug-related cardiotoxicity.
Detection - Circulating
"Detection of circulating...
Wake Up To Breaking News!